Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 13,890	$ 11,092
Accounts receivable, net of allowance for doubtful accounts of $2,436 and $2,730 at 2020 and 2019, respectively	126,872	131,579
Inventories	52,263	50,163
Prepaid expenses	14,328	15,951
Income taxes receivable	5,899	6,527
Other current assets	6,455	5,925
TOTAL CURRENT ASSETS	219,707	221,237
PROPERTY, PLANT AND EQUIPMENT, net	123,112	123,506
RIGHT OF USE ASSETS	74,943	75,697
INTANGIBLES, net	8,973	17,450
GOODWILL	99,376	213,425
DEFERRED TAX ASSETS, net	71,219	67,312
OTHER ASSETS	49,279	56,046
TOTAL ASSETS	646,609	774,673
CURRENT LIABILITIES:
Accounts payable	37,054	35,611
Accrued payroll and related costs	28,563	26,689
Taxes other than payroll and income	5,869	8,366
Unearned revenues	11,210	13,381
Operating lease liabilities	12,583	11,841
Income taxes payable	5,056	6,324
Other current liabilities	8,112	9,382
TOTAL CURRENT LIABILITIES	108,447	111,594
LONG-TERM DEBT, net	302,420	305,283
LONG-TERM OPERATING LEASE LIABILITIES	60,162	64,660
DEFERRED COMPENSATION	46,358	50,485
DEFERRED TAX LIABILITIES, net	23,871	27,338
OTHER LONG-TERM LIABILITIES	35,277	33,173
COMMITMENTS AND CONTINGENCIES
EQUITY:
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding	0	0
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 44,796,252 issued and 44,444,177 outstanding at 2020 and 44,796,252 issued and 44,465,562 outstanding at 2019	1,148	1,148
Additional paid-in capital	60,982	51,872
Retained earnings	41,007	160,539
Accumulated other comprehensive income (loss)	(8,239)	(6,330)
Treasury shares (at cost), 352,075 at 2020 and 330,690 at 2019	(29,182)	(29,364)
Total Core Laboratories N.V. shareholders' equity	65,716	177,865
Non-controlling interest	4,358	4,275
TOTAL EQUITY	70,074	182,140
TOTAL LIABILITIES AND EQUITY	$ 646,609	$ 774,673